Xue-Chun Lu
-
- Immune Cell Function and Interaction 2
-
- Viral-associated cancers and disorders 2
-
- Cancer-related molecular mechanisms research 4
-
- Lymphoma Diagnosis and Treatment 9
-
- RNA modifications and cancer 4
-
- CNS Lymphoma Diagnosis and Treatment 2
-
- Erythrocyte Function and Pathophysiology 2
-
- Ferroptosis and cancer prognosis 2
- Cited by
- HematologyImmunologyOncology
- Journals
- SHILAP Revista de lepidopterología (1 paper)PLoS ONE (1 paper)Scientific Reports (1 paper)
- Partner nations
- ChinaPhilippinesUnited States
In The Last Decade
Xue-Chun Lu
31 papers receiving 207 citations
Peers
Comparison fields: 5 of 66
- Hematology 30
- Immunology 39
- Oncology 45
- Cardiology and Cardiovascular Medicine 37
- Cancer Research 17
Countries citing papers authored by Xue-Chun Lu
This map shows the geographic impact of Xue-Chun Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xue-Chun Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xue-Chun Lu more than expected).
Fields of papers citing papers by Xue-Chun Lu
This network shows the impact of papers produced by Xue-Chun Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xue-Chun Lu. The network helps show where Xue-Chun Lu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xue-Chun Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 7 | |
| 3 | 2023 | 3 | |
| 4 | 2022 | 1 | |
| 5 | 2021 | 4 | |
| 6 | 2021 | 20 | |
| 7 | 2020 | 17 | |
| 8 | 2018 | 15 | |
| 9 | 2013 | 13 | |
| 10 | 2012 | 14 | |
| 11 | 2012 | 6 | |
| 12 | 2012 | 14 | |
| 13 | 2012 | 1 | |
| 14 | 2012 | 2 | |
| 15 | 2011 | 9 | |
| 16 | [Clinical analysis of 12 acute leukemia patients aged over 80 years]. | 2011 | 1 |
| 17 | 2011 | 30 | |
| 18 | 2009 | 0 | |
| 19 | [Methylation status of ZO-1 gene in patients with myelodysplastic syndrome]. | 2008 | 3 |
| 20 | [Detection of blood dissemination during the operation of lung cancer and its significance]. | 2005 | 2 |
About Xue-Chun Lu
Xue-Chun Lu is a scholar working on Pathology and Forensic Medicine, Gastroenterology and Cancer Research, having authored 35 papers that have together received 212 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (9 papers), Cancer-related molecular mechanisms research (4 papers), RNA modifications and cancer (4 papers), CNS Lymphoma Diagnosis and Treatment (2 papers), Erythrocyte Function and Pathophysiology (2 papers), Ferroptosis and cancer prognosis (2 papers), Viral-associated cancers and disorders (2 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Hematology (30 citations), Immunology (39 citations) and Oncology (45 citations). Xue-Chun Lu has collaborated with scholars based in China, Philippines and United States. Frequent co-authors include Bo Yang, Ruili Yu, Haomin Zhang, Hui Fan, Ran Zhang, Hongli Zhu, Lili Cai, P. F. He, Guangxin Yuan and Liping An. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.